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orafenib is indicated for the treatment of
advanced renal cell carcinoma (RCC), with
specific recommendations by the National
Comprehensive Cancer Network (NCCN) as
second-line therapy for metastatic RCC after pro-
gression on initial systemic cytokine therapy (cate-
gory 1) or tyrosine kinase inhibitor therapy (category
2A), and as first-line therapy only in select patients
(category 2A).1,2
Sorafenib is additionally approved for use in
unresectable or metastatic hepatocellular carcinoma
(HCC), with specific NCCN recommendations for
patients with Child-Pugh class A liver functionevier Inc.
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Open access under CC BY-NC-ND license.(category 1) and for selected patients with less
preserved Child-Pugh class B liver function (category
2B).1,3 The lower level of evidence for patients with
Child-Pugh class B is a result of the smaller number
of patients with more advanced liver dysfunction in
the phase III HCC trials; approximately 3% of
patients in each study had Child Pugh class B liver
function.4,5 Though the product literature does not
recommend dose modification in patients with mod-
erate (Child-Pugh class B) liver dysfunction,1 some
clinical data have demonstrated higher sorafenib
toxicity in patients with Child-Pugh class B liver
function, as well as a correlation between elevated
bilirubin levels and possible hepatotoxicity.6,7 How-
ever, the worse outcomes in patients with Child-
Pugh B status may be due to the natural (faster)
disease progression of cirrhosis in these patients,
rather than related to sorafenib.6 Data from the first8
and second9 interim analyses of GIDEON, a non-
interventional, phase IV study in patients with HCC,
indicated that the Child-Pugh status does not appear
to influence sorafenib starting dose8 and that safety
may be similar regardless of Child-Pugh A or B
status.9 In the final analysis from GIDEON, data
showed that sorafenib safety and dosing were gen-
erally consistent across patients, irrespective of liver
function. The overall incidence rates of AEs and
drug-related AEs were similar across Child-Pugh
subgroups. However, as expected, serious AEs8 S17
C.M. Walko and C. GrandeS18(SAEs) increased as Child-Pugh status worsened
(Child-Pugh A status: 36.8% for all patients and
8.8% treatment-related; Child-Pugh B: 60.4% for all
patients and 14.1% treatment-related).10
The efficacy and safety of sorafenib has been
demonstrated in phase III HCC4,5,11 and RCC12,13
clinical trials and in phase II trials in patients with
locally advanced/metastatic radioactive iodine (RAI)–
refractory differentiated thyroid cancer (DTC)14–17
and locally advanced or metastatic human epidermal
growth factor receptor 2 (HER2)−negative breast
cancer (MBC),18 leading to phase III studies in these
tumor types. A phase III trial in patients with DTC
has recently been completed,19 and a phase III
MBC trial is currently underway.20 Several sorafenib
phase III trials in patients with HCC,21,22 unresec-
table (stage III) and malignant (stage IV) mela-
noma,23,24 non−small cell lung cancer (NSCLC),25–27
pancreatic cancer,28 as well as a phase II study in
metastatic uveal melanoma,29 ovarian cancer,30 and
colorectal cancer31 did not meet their primary end
points. However, other phase II studies in multiple
tumor types, including patients with NSCLC, HCC,
MBC, and gastric, colorectal and ovarian cancers, and
uveal melanoma are ongoing (per a search in Clin-
icalTrials.gov) or have recently been completed with
promising results, as have been reported in confer-
ence abstracts.32,33 Toxicities arising from both the
positive and negative studies are consistent and
similar to other drugs in its class.34–38 For example,
drug-related AEs that may influence a patient’s quality
of life (ie, dermatologic toxicities, gastrointestinal
toxicities, and fatigue) are commonly reported
(Tables 1 and 2).4,5,8,11–15,17,18,39–44 Here we will
focus on the pivotal trials in HCC and RCC, as well
as the two phase II studies that led up to the ongoing
phase III trials in DTC and MBC, to show differences
and similarities across tumor types.SORAFENIB MECHANISM OF ACTION
Sorafenib is an oral multi-targeted tyrosine kinase
inhibitor with anti-proliferative, anti-angiogeneic,
and pro-apoptotic effects. These effects are mediated
through inhibition of numerous tyrosine kinases.
The anti-tumor effects of the drug and concentra-
tions required for effect vary based on the signaling
pathway driving tumor growth.45 In malignant cells
primarily driven by one activating mutation, sorafe-
nib exerts its anti-proliferative effects in the nano-
molar concentration range. Examples of this include
RET variants in thyroid cancer, Flt-3 mutations in
leukemic cells, and cKIT mutations in gastrointesti-
nal stromal tumors.45
Sorafenib was initially developed as a potent
inhibitor of Raf serine/threonine kinase isoforms,
with the most potent activity in vitro being againstRaf-1, followed by wild-type B-Raf, and then the
V600E-mutated B-Raf.46 The anti-angiogenic effects
of sorafenib are primarily mediated by inhibition of
vascular endothelial growth factor receptor
(VEGFR)-1, VEGFR-2, and VEGFR-3, in addition to
platelet-derived growth factor receptor (PDGFR)-β46
(Figure 1). Sorafenib also has demonstrated pro-
apoptotic properties; however, the mechanism of
this activity is not fully understood.45SORAFENIB METABOLISM AND DRUG−DRUG
INTERACTIONS
Sorafenib is metabolized in the liver primarily by
oxidation via cytochrome P-450 (CYP) 3A4 and
glucuronidation via UGT1A9.1 For this reason,
potent inducers or inhibitors of CYP3A4 may result
in altered concentrations of sorafenib. In vitro
studies of sorafenib in human liver microsomes also
support the competitive inhibition of numerous CYP
enzymes and P-glycoprotein,1 which suggests the
possibility of drug−drug interactions. However, a
clinical trial assessing the pharmacokinetic effects
of sorafenib on midazolam, omeprazole, and dextro-
methorphan did not support clinically relevant
changes in these substrates for CYP3A4, CYP2C19,
and CYP2D6, respectively.47 This suggests that a
clinically relevant interaction between concurrent
use of sorafenib and drugs metabolized or affecting
these enzymes is unlikely. However, therapeutic
drug monitoring for those with a narrow therapeutic
index is still recommended.SORAFENIB MODE OF ADMINISTRATION
AND DOSAGE
The recommended starting dose for the treatment
of patients with RCC and HCC is 400 mg orally twice
daily without food (at least 1 hour before or 2 hours
after a meal).1 Dose reductions to 400 mg once daily
or once every other day may be required based on a
patient’s ability to tolerate the dose. In two large
phase III approval trials, dose reductions due to AEs
were required in 13% and 26% of patients, and
treatment interruptions were required in 21% and
44% of patients with RCC and HCC, respectively.4,12
The most common AEs responsible for dose reduc-
tion or interruption in both disease groups were
diarrhea, hand–foot skin reaction (HFSR), and rash or
skin desquamation.COMMON AEs IN PATIENTS TREATED WITH
SORAFENIB
The most common AEs associated with sorafenib
treatment included dermatologic toxicities (eg,
Table 1. Incidence of Treatment-Related AEs in the Pivotal Phase III Placebo-Controlled Clinical Trials
(HCC and RCC)*
HCC†4,5 RCC‡13
Sorafenib
(n ¼ 446)
Placebo
(n ¼ 377)
Sorafenib
(n ¼ 452)
Placebo
(n ¼ 451)
Crossover
From Placebo
to Sorafenib
(n ¼ 216)
Drug-
related
AEs, %
Any
Grade
Grade
3/4
Any
Grade
Grade
3/4
Any
Grade
Grade
3/4
Any
Grade
Grade
3/4
Any
Grade
Grade
3/4
HFSR 21–45 8–11 3 o1 33 6 8 o1 37 7
Rash/
desquamation
16–20 1 7–11 0 31 0 4 0 29 4
Diarrhea 26–39 6–8 5–11 0–2 48 3 11 1 48 5
Fatigue 20–22 3 8–16 1–3 29 3 16 1 25 5
Hyper-
tension
5–19 2 1–2 0–1 17 4 1 0 13 4
⁎ Phase III studies that informed the US Food and Drug Administration approval of sorafenib are included (phase III studies that are
ongoing or that did not meet their primary end points are not included in this table).
† Includes patients in the SHARP (N¼599) and Asia-Paciﬁc (N ¼ 224) trials. In both trials, patients received oral sorafenib 400 mg or
placebo, twice daily, in 6-week cycles.
‡ Includes patients in the TARGET trial (N¼903). Patients received continuous, twice-daily treatment with either sorafenib 400 mg (n ¼
452) or placebo (n ¼ 451); 48% (n ¼ 216) of patients from the placebo group crossed over to sorafenib after a planned analysis of
progression-free survival demonstrated an advantage in the sorafenib group.
Abbreviations: AEs, adverse events; HCC, hepatocellular carcinoma; HFSR, hand–foot skin reaction; RCC, renal cell carcinoma.
Nurse and Pharmacist Perspective S19HFSR and rash), diarrhea, fatigue, and hyperten-
sion.1,4,5,11–18,39,40,48 HFSR and rash are usually
Common Terminology Criteria for Adverse Events
(CTCAE)49 grade 1 or grade 2, appear within 6 weeks
of treatment initiation,1 and, with increased severity
(grade 2 or 3), may significantly (P ¼ .042)50 impact
overall quality of life.51Table 2. Incidence of Treatment-Related AEs in Pha
DTC†17
Sorafenib (N ¼ 30)
S
Capec
Drug-Related AEs, % Grade 1/2 Grade 3/4 Any G
HFSR 83 10 90
Rash/desquamation 70 10 22
Diarrhea 73 7 58
Fatigue 60 3 15
Mucosal inﬂammationǁ NR NR 33
Hypertension 30 13 18
⁎ Completed phase II studies that met their primary endpoint, are pub
that are ongoing or did not meet their primary end points are not inclu
† Patients with DTC received sorafenib 400 mg orally twice daily.
‡ Includes patients in the SOLTI-0701 trial (N¼229). Patients with M
1,000 mg/m2 orally twice daily for days 1−14 of each 21-day cycle þ
unacceptable HFSR toxicity in the sorafenib arm, the follow-up phase
starting dose (twice daily dosing; 600 mg total daily dose) and practica
§ In the SOLTI-0701 breast cancer study, capecitabine has some over
ǁ Capecitabine-related toxicity.
Abbreviations: AEs, adverse events; DTC, locally advanced/metastati
HFSR, hand–foot skin reaction; MBC, locally advanced or metastaticDiarrhea, which most frequently presents as
grade 1 or 2,1 commonly occurs after the first cycle
of sorafenib treatment in patients with HCC52 or
RCC and later (approximately 3–4 months) in
patients with DTC (author observations) and
can also reduce quality of life if not managed
effectively.se II Clinical Trials (DTC and MBC)*
MBC‡18
orafenib þ
itabine (n ¼ 112)
Placebo þ Capecitabine§
(n ¼ 112)
rade Grade 3/4 Any Grade Grade 3/4
44‡ 66 14
4 8 0
6 30 4
3 13 1
1 21 4
1 12 2
lished, and led to phase III studies are included. Phase II studies
ded.
BC were randomly assigned to ﬁrst- or second-line capecitabine
sorafenib 400 mg orally twice daily or placebo. Due to the
III RESILIENCE trial (ongoing) implemented a lower sorafenib
l HFSR prevention and management strategies.20,56
lapping toxicities with sorafenib.
c radioactive iodine−refractory differentiated thyroid cancer;
breast cancer; NR, not reported.
Figure 1. Sorafenib mechanism of action: tumor proliferation and angiogenesis. Adapted from Mol Cancer Ther.
2008;7:3129-40, Wilhelm SM et al, Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and
VEGF and PDGF receptor tyrosine kinase signaling, with permission from American Association of Cancer Research.47
Abbreviations: ERK, extracellular signal-related kinase; HIF, hypoxia-inducible factor; MEK, Raf-mitogen-activated protein
kinase/ERK; P, phosphorylation; PDGF, platelet-derived growth factor; PDGFR, PDGF receptor; TGF, transforming growth
factor; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; VHL, von Hippel-Lindau tumor suppressor gene.
C.M. Walko and C. GrandeS20Causes of fatigue are typically multifactorial, includ-
ing the underlying disease, treatment, dehydration,
diarrhea, anemia, pain, sleep disturbances, depres-
sion, or malnourishment. Fatigue also may be related
to comorbid endocrine disorders such as hypothyr-
oidism, hypogonadism, and adrenal insufficiency.53
Hypertension, when it occurs, is manageable with
the use of antihypertensive agents. CTCAE toxicity
grading for these AEs is described in Table 3.MANAGEMENT OF GRADE 1 AND GRADE
2 AES
The goal of treatment for grades 1 and 2 sorafenib-
related AEs is to continue the patient on their
recommended dose of sorafenib medication without
interruption, as recommended in the package insert.1
More severe toxicities (CTCAE grades 3 and 4) may
require temporarily stopping sorafenib or reducing
the dose.1 Management of grade 1 and 2 AEs are
similar between tumor types, including HCC, RCC,
and DTC. However, there are a few notable differ-
ences, which are discussed in the following sections.
Dermatologic Toxicities (HFSR and rash)
HFSR
Management strategies for grade 1 and grade
2 dermatologic toxicities associated with sorafenibtreatment are largely empiric.51,54 There have been
no evidence-based approaches from randomized clin-
ical trials, with the exception of one phase II study by
Ren et al (prophylactic effect of urea-based cream on
HFSR in HCC),55 and a standard of care has not yet
been adopted. However, severity of HFSR can be
reduced through patient education, proactive man-
agement, and early detection. Although no standard
of care has yet been adopted, it may be noted that in
the ongoing phase III RESILIENCE trial in patients
with HER2-negative locally advanced or MBC, prac-
tical HFSR prevention and management strategies
have been developed and implemented, which
includes a lower sorafenib starting dosage (twice-
daily dosing, 600-mg total daily dose)20,56 compared
with the phase II SOLTI-0701 trial (400 mg, twice
daily), in which unacceptable HFSR toxicities (90%
all grades; 44% grade 3) were observed (see
Table 2).18 Of note, these breast cancer studies are
in combination with capecitabine, which has some
overlapping toxicities to sorafenib, while the sorafe-
nib trials in patients with HCC and RCC included
single-agent sorafenib only.
Therefore, successful management of HFSR is
dependent upon a strong partnership between the
multidisciplinary healthcare team and the patient.
Prompt intervention is advised when HFSR occurs,
because early symptoms can be resolved quickly
with minimum effort.51
Table 3. CTCAE (v3.0): AEs That May Occur During Sorafenib Treatment
AE
CTCAE (v3.0) Toxicity Grading49
Grade 1 (Mild) Grade 2 (Moderate) Grade 3 (Severe)
Grade 4 (Life-
threatening
or disabling)
Dermatologic
HFSR Minimal skin changes
or dermatitis (eg,
erythema) without
pain
Skin changes (eg,
peeling, blisters,
bleeding, edema)
or pain, not
interfering with
function
Ulcerative dermatitis
or skin changes
with pain
interfering with
function
N/A
Rash/
desquamation
Macular or popular
eruption or
erythema without
associated
symptoms
Macular or popular
eruption or
erythema with
pruritus or other
associated
symptoms;
localized
desquamation or
other lesions
coveringo50%
BSA
Severe, generalized
erythroderma or
macular, papular or
vesicular eruption;
desquamation
covering ≥50%
BSA
Generalized
exfoliative,
ulcerative,
or bullous
dermatitis
Diarrhea Increase ofo4 stools/
day over baseline;
mild increase in
ostomy output
compared with
baseline
Increase of 4–6 stools/
day over baseline;
IV ﬂuids
indicatedo24
hours; moderate
increase in ostomy
output compared
with baseline; not
interfering with
ADL
Increase of ≥7 stools/
day over baseline;
incontinence; IV
ﬂuids ≥24 hours;
hospitalization;
severe increase in
ostomy output
compared with
baseline;
interfering with
ADL
Life-
threatening
consequen-
ces (eg,
hemody-
namic
collapse)
Fatigue Mild fatigue over
baseline
Moderate or causing
difﬁculty
performing some
ADL
Severe fatigue
interfering with
ADL
Disabling
Hypertension* Asymptomatic,
transient (o24
hours) increase
by420 mmHg
(diastolic) or
to4150/100 if
previously WNL;
intervention not
indicated
Recurrent or
persistent (≥24
hours) or
symptomatic
increase by420
mmHg (diastolic)
or to4150/100 if
previously WNL;
monotherapy may
be indicated
Requiring41 drug or
more intensive
therapy than
previously
Life-
threatening
consequen-
ces (eg,
hyperten-
sive crisis)
⁎ Adult only; does not include pediatric grades.
Abbreviations: ADL, activities of daily living; AE, adverse event; BSA, body surface area; CTCAE (v3.0), Common Terminology Criteria
for Adverse Events, version 3; HFSR, hand–foot skin reaction; IV, intravenous; N/A, not applicable; WNL, within normal limits.
Nurse and Pharmacist Perspective S21The primary proactive management and treat-
ment approach for HFSR is hydration of the skin
with topical urea-based creams (Figure 2).1,51,54,57Data from a randomized phase II study of patients
with advanced HCC treated with sorafenib (N ¼
871) showed that prophylactic use of a 10% urea-
Prior to 
sorafenib 
treatment
• All of  the above, plus…
• Dosing changes may be considered
• The goal is to bring HFSR to grade 0 or 
grade 1 toxicity
Throughout 
sorafenib 
treatment, 
regardless 
of HFSR or 
no HFSR 
• Patient education
 – Review signs and symptoms of  HFSR, including anticipated onset and duration
 – Encourage open communication: patient should report signs and symptoms immediately 
to their healthcare team
 – Stress the value and importance of  daily skin care
• Obtain a pretreatment consult with a podiatrist for callus removal
• Daily skin care: apply 10% urea-based cream TID on hands and feet to soften 
hyperkeratosis and decrease epidermal thickness
• All of  the above, plus…
• Ongoing patient education
 – Reinforce daily skin care regimen
• Schedule regular follow-up for patients to assess skin, particularly in the first 2 weeks to 
3 months of  treatment 
• Recommend that patients
 – Wear thick cotton socks and comfortable, supportive shoes to protect feet
 – Wear cotton gloves to protect hands and rubber gloves when washing dishes
 – Avoid hot water
Grade 1*
HFSR
Grade 2*
HFSR
Grade 3*
HFSR
• All of  the above, plus…
• Follow up with patient every 2 weeks
• Use 20–40% urea cream (instead of  10%)
• Dosing changes not recommended
• Dose reduction and/or interruption 
may be considered, based on clinical 
judgment and patient preference
• Follow guidelines for grade 2 
HFSR above
• Dosing changes generally not needed
• However, dose reduction to 400 mg 
daily (7–28 days) may be considered
 – If  toxicity does not resolve to grade 
0 or 1 HFSR, interrupt for 7 days 
until resolved
 – Re-initiate sorafenib at reduced 
(400 mg) dose; increase to full dose 
if  HFSR is maintained at grade 0 or 
1 toxicity
• For 2nd and 3rd occurrence, follow 
guidelines for 1st occurrence above
• For 4th occurrence, sorafenib 
discontinuation based on clinical 
judgment and patient preference
• All of  the above, plus…
• Symptomatic relief, if  needed:
 – Anti-inflammatory (eg, ibuprofen 
600 to 800 mg every 8 hours, taken 
with food)
 – Pain control: topical (lidocaine 2% or 
clobetasol 0.05%) or oral opioids 
(codeine 15–30 mg every 4 hours, as 
needed); pregabalin (50 mg, titrate to 
75 mg PO TID)
• The goal is to bring HFSR to grade 0 or 
1 toxicity
Figure 2. Algorithm for the management of TKI-related HFSR (recommendations from Lacouture Oncologist 200851;
Manchen 201157; Anderson 200954; Nexavar PI1; Codeine Sulfate PI75; Lyrica PI76; Ibuprofen PI77; and author
recommendations). Common Terminology Criteria for Adverse Events (CTCAE) v3.0.49 Abbreviations: HFSR, hand–foot
skin reaction; PI, prescribing information; PO, orally; TID, 3 times a day; TKI, tyrosine kinase inhibitor.
C.M. Walko and C. GrandeS22based cream three times daily, plus best supportive
care versus best supportive care alone reduced the
incidence of all-grade (Po.001) and grade Z2 (P ¼
.004) HFSR and also delayed the time to first
occurrence (84 v 34 days; Po.0001).55
Wearing comfortable, supportive shoes can help
minimize episodes of HFSR on the feet. Frequent
inspection of feet for calluses is encouraged, as well
as associated management by a podiatrist.51,54
Although HFSR may be managed primarily
through hydration, depending on the tumor type,
the inflammation associated with HFSR may be
diminished by cautiously adding a nonsteroidal anti-
inflammatory drug (NSAID) with food, thereby ena-
bling patients to remain at their recommended dose1of sorafenib. In disease states such as RCC or HCC,
extra caution for using NSAIDs may be warranted.
The addition of a proton pump inhibitor such as
omeprazole (Prilosec; AstraZeneca, Wilmington, DE)
or esomeprazole (Nexium; AstraZeneca, Wilming-
ton, DE) may be helpful in reducing the gastro-
intestinal injury that may be caused by NSAIDs.58,59Generalized Rash
Management for generalized rash is similar to that
for HFSR, including the use of topical therapies,1
such as corticosteroid creams and ointments that
have mild anti-inflammatory properties, for sympto-
matic relief.60,61 Preventive, regular use of thick,
Nurse and Pharmacist Perspective S23alcohol-free moisturizers is recommended to mini-
mize skin irritation. Application of sunscreen with
sun protective factor of at least 15 every morning
and prior to direct sun exposure will protect skin
from the increased sun sensitivity. Sensitivity to
sunlight also may be exacerbated by some antibiotics
(specifically tetracyclines, which may be used to
reduce inflammation). For pruritis, oral antihist-
amines such as diphenhydramine (Benadryl;
McNeil-PPC, Inc, Fort Washington, PA) or hydrox-
yzine (Atarax; Majedo Corp, Houston, TX) may offer
some relief.62 Nonsedating antihistamines also
may be considered for longer treatment courses.
However, the authors recommend that patients
avoid topical antihistamines, which have been noted
to worsen the rash in some patients (author
experience).Diarrhea
Prior to making recommendations for diarrheal
management, a thorough assessment of signs and
symptoms, including severity, duration, volume,
and patterns of diarrheal episodes should be
undertaken.63
As with all AEs, patients should be advised to
immediately report symptoms of diarrhea or abdomi-
nal distress, such as cramping, to their healthcare
team for early and effective management. Early
intervention can help a patient prevent associated
sequelae, such as dehydration and electrolyte imbal-
ance, and may enable patients to remain on their
recommended sorafenib dose.
Maintaining hydration with the intake of addi-
tional electrolyte-containing oral fluids64 is critical as
dehydration, which may be caused by under-
assessed or inadequately treated diarrhea, can cause
an imbalance in electrolytes63 and lead to other
symptoms, such as fatigue.53 Episodes of diarrhea,
particularly grade 1 or 2, may be effectively managed
by good supportive care without interruption of
treatment (Figure 3).65
Patient education, including learning which foods
to avoid, is very helpful in managing diarrhea
symptoms.66 Often, patients will try to find a pattern
to their episodes of diarrhea but can be quite
frustrated if one does not exist. However, if a
connection can be made to a particular food, dietary
adjustments may be made. Generally, patients
should avoid foods that are high in insoluble fiber
and fat and increase the amount of soluble, low-fiber
foods.67
For episodal (acute) management, patients may be
instructed to take loperamide (Imodium; McNeil-
PPC) at an initial dose of 4 mg, followed by 2 mg
every 4 hours or after each loose stool,63 increasing
the dose until the desired effect is achieved.Preventive therapy with loperimide 2 mg 30 minutes
before taking their dose of sorafenib68 may be
effective for patients who frequently experience
diarrhea after dosing. However, preventive therapy
should be reserved for those patients for whom a
complete history of diarrhea incidence is obtained,
including identification of a pattern to the diarrheal
episodes.67 For patients for whom loperimide is
effective and who are worried about loose stools
during the night, it is recommended that they take
loperimide before bedtime. Generally, if 4 mg every
4 hours is not effective, another drug, such as
diphenoxylate/atropine (Lomotil; Pfizer, Inc., New
York, NY), may be added.
Fatigue
Educating patients on the multifactoral causes of
fatigue, as well as what to expect prior to beginning
treatment, can help address some contributors to
fatigue (eg, dehydration, depression, loss of appetite,
diarrhea, and pain) while enabling patients to better
manage their daily activities by working effectively
around episodes of fatigue. Patients should be
encouraged to report any symptoms of fatigue and
keep an open dialogue with their healthcare team.
Patients also should be instructed to remain
hydrated, since dehydration may add to symptoms
of fatigue.53 For patients who also are experiencing
diarrhea, increasing hydration above the recom-
mended 64 ounces of fluid per day is important.67
Fatigue that is caused or exacerbated by weight
loss as a consequence of, for example, changes in
taste or anorexia can be treated by the addition of an
appetite stimulant, such as dronabinol (Marinol;
AbbVie, Inc, North Chicago, IL).53,69 Other possible
causes of fatigue should be investigated and
addressed, including hypothyroidism, pain, poor
sleep patterns, and psychiatric issues (ie, depression
and/or anxiety).53
Energy management techniques can be employed
to help manage fatigue.53 This may include restruc-
turing a patient’s day to incorporate resting periods
as needed. Inclusion of weight-bearing upper and
lower body exercises can help relieve fatigue, and
it is recommended that patients begin a strength-
training exercise program prior to initiating therapy
with sorafenib.
Hypertension
Frequent monitoring of blood pressure by the
healthcare staff (every 2 weeks during the first
2 months of sorafenib treatment) is the key to early
treatment and resolution of hypertension. If able,
patients should be instructed to monitor their own
blood pressure in between visits and keep a journal
that they can share with their healthcare team.
Unresolved 
diarrhea
If loperamide 
is ineffective, 
consider…
Patient education
• Encourage patient to report symptoms immediately to healthcare team for rapid intervention and resolution
• Identify foods and beverages to eat and to avoid
• Ask patient to maintain a journal of bowel patterns (ie, frequency, amount, and consistency of stool) to share with 
their healthcare team
Patient evaluation
• Obtain history of baseline and current bowel movements
• Probe for specifics, including when change in patterns began; frequency, amount, consistency, and color of stool; 
incontinence episodes; and the presence of blood in the stool
• Assess current diet and review medication profile, including over-the-counter products
• Assess patient for signs and symptoms of dehydration
noitnevretni cigolocamrahPtnemeganam cigolocamrahpnoN
Maintain hydration
• Drink 64–96 ounces of electrolyte-containing 
fluids daily
 – eg, broth; Gatorade; Pedialyte
Dietary management
• Eat frequent, small meals
• Dietary supplements (eg, soluble fiber; pectin) 
may be helpful
• Foods to eat
 – Low-fiber foods that build stool consistency 
(eg, applesauce; rice; bananas; white toast)
 – Plain foods (eg, non-whole wheat pasta)
 – High potassium-containing foods 
(eg, skinless potatoes; lactose-free milk; 
bananas; peach and apricot nectar)
• Foods to avoid
 – Lactose-containing products (dairy)
 – High-fiber foods (eg, whole wheat breads 
and cereals; raw fruits and vegetables)
 – High-fat and greasy foods
 – Nuts and seeds
 – Spicy foods
 – Caffeine-containing foods and drinks
 – Alcohol
 – Carbonated drinks
Nonopioid
• Episodal diarrhea
 – Loperamide (eg, Imodium) 4 mg initial 
dose, followed by 2 mg every 4 hours after 
each loose stool
 • Continue dosing until desired affect 
is achieved
• Preventive  treatment
 – If diarrheal pattern is established, use 
loperamide 2–4 mg, 30 minutes prior to 
sorafenib dose before bedtime, to prevent 
nighttime stooling
Opioids
• Diphenoxylate and atropine (eg, Lomotil), 
5 mg (2 × 2.5-mg tablets) loading dose, 
followed by 2.5 or 5 mg, 4 times/day
• Opium tincture, 0.3–1 mL PO every 2–6 hours 
until controlled
Figure 3. Algorithm for the management of CTCAE* grade 1 and grade 2 diarrhea (recommendations from Maroun
200765; Kornblau 200074; Benson 200463; Lomotil PI78; Wood 200779; Opium Tincture PI80; Nexavar PI1; and author
recommendations). CTCAE v3.0.49 Abbreviation: CTCAE v3.0, Common Terminology Criteria for Adverse Events, version
3.0; PI, prescribing information; PO, orally.
C.M. Walko and C. GrandeS24For patients who become hypertensive, current
guidelines by the Joint National Committee (JNC) for
the prevention, detection, evaluation, and treatment
of high blood pressure (JNC 7)70 may be followed
(Figure 4). Hypertension is often easily managed
with a thiazide-type diuretic, a beta-blocker, an
angiotensin-converting enzyme inhibitor, or an
angiotensin receptor blocker, alone or in combina-
tion. The calcium channel blockers diltiazem and
verapamil have the potential to interact with sorafe-
nib via the CYP34A pathway and should therefore be
avoided.71 Additionally, there is some evidence that
nifedipine may increase the secretion of VEGF,72
which would make this agent less desirable. If
preexisting hypertension is well controlled with a
particular agent (with the exception of those that
should be avoided due to potential interactions withsorafenib) the patient should be able to remain on
that treatment. In the sorafenib phase 2 placebo-
controlled discontinuation RCC trial (N ¼ 202), anti-
hypertensive medication was initiated in 46% of
patients; once hypertension was controlled, patients
remained on their anti-hypertensive medication
without frequent adjustment.73SUMMARY
The most common grade 1 and grade 2 AEs
experienced by patients treated with sorafenib (HFSR,
rash, diarrhea, fatigue, and hypertension) can fre-
quently be managed without the need for dose
reduction or discontinuation of sorafenib treatment.
Proactive management, early recognition, and inter-
vention of these AEs may prevent symptoms or
Lifestyle Modifications
Initial Drug Choices
Not at Goal 
Blood Pressure
Lifestyle Modifications 
With Compelling 
Indications
Not at Goal Blood Pressure (<140/90 mmHg)
(<130/80 mmHg for those with diabetes 
or chronic kidney disease)
Without Compelling 
Indications
Stage 1 Hypertention
(SBP 140–159 or
DBP 90–99 mmHG)
Thiazide-type diuretics
for most. May consider
ACEI, ARB, BB, CCB,
or combination
Other antihypertensive
drugs (diuretics, ACEI, 
ARB, BB, CCB) 
as needed
Optimize doses or add additional drugs
until goal blood pressure is achieved. 
Consider consultation with hypertension specialist
Stage 2 Hypertention
(SBP ≥160 or
DBP ≥100mmHG)
Two-drug combination
for most (usually 
thiazide-type diuretic 
and ACEI, or ARB, 
or BB, or CCB)
Figure 4. Algorithm for the treatment of hypertension* (JNC 7 Guidelines).70 Source: US Department of Health and
Human Services. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of
High Blood Pressure (JNC 7 guidelines).70 Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin
receptor blocker; BB, beta blocker; CCB, calcium channel blocker; DBP, diastolic blood pressure; SBP, systolic blood
pressure.
Nurse and Pharmacist Perspective S25decrease their severity, allowing the patient an opti-
mal treatment experience. Patients are also more
likely to remain on treatment if they are guided over
the difficult initial 8–12 weeks of therapy, during
which time the development of AEs following sorafe-
nib treatment initiation are most likely to occur.
Patients who are well educated about the poten-
tial side effects and prevention/management strat-
egies may be better able to adapt to daily routines
that enhance their quality of life. Further, patients
who understand the rationale behind proactive
monitoring and the importance of timely reporting
of AEs to their healthcare team will be empowered
to take control of their health and their daily lives
where they may otherwise feel overwhelmed.Patient education, proactive management, and
establishing and maintaining open communication
between patients and the multidisciplinary medical
staff (including physicians, nurses, pharmacists, and
dieticians) are crucial to the effective management of
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